Novo Nordisk A/S has been spending huge sums to boost manufacturing capacity to meet demand for its GLP-1 drugs and the Danish major's latest megabucks investment is good news for workers in the US but a major blow for Ireland.
Marking "one of the largest manufacturing investments in Novo’s history," the Copenhagen-based group has announced plans to invest $4.1bn to build a second fill and finishing facility in Clayton, North Carolina "to grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?